Starting Jan. 1, 2022, bill Medicare Advantage plans for administration of COVID‑19 vaccines and monoclonal antibody treatments

Beginning Jan. 1, 2022, the Centers for Medicare & Medicaid services will require Medicare Advantage plans to cover the cost to administer COVID-19 vaccines (including approved booster doses) and monoclonal antibody products to treat COVID-19, with no out-of-pocket costs for members.

For dates of service on or after Jan. 1, 2022, submit claims for the administration of vaccines and monoclonal antibody treatments to Blue Cross Blue Shield of Michigan or Blue Care Network for members with Medicare Plus Blue℠ or BCN Advantage℠ plans.

Note: If your patient scheduled an office visit on or after Jan. 1, 2022, for any other reason than getting the vaccine or monoclonal antibody treatments, bill the usual office visit charge.

More information

For more information on the COVID-19 vaccine, refer to CMS’ COVID-19 toolkit** for health care providers.
For more information on monoclonal antibody treatment, see the Monoclonal Antibody COVID-19 Infusion webpage** of CMS’ COVID-19 toolkit for health care providers.

Reminder

For dates of service on or after Oct. 1, 2021, cost share applies for any treatment related to COVID-19, other than monoclonal antibody treatment, for Medicare Plus Blue and BCN Advantage members.

None of the information in this article is intended to be legal advice and, as such, it remains the providers’ responsibility to ensure that all coding and documentation are done in accordance with all applicable state and federal laws and regulations.

**Blue Cross Blue Shield of Michigan and Blue Care Network don’t own or control this website.